Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
- PMID: 22010014
- PMCID: PMC3221519
- DOI: 10.1200/JCO.2010.34.3293
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
Abstract
Purpose: To assess the feasibility of adding dose-intensive topotecan and cyclophosphamide to induction therapy for newly diagnosed high-risk neuroblastoma (HRNB).
Patients and methods: Enrolled patients received two cycles of topotecan (approximately 1.2 mg/m(2)/d) and cyclophosphamide (400 mg/m(2)/d) for 5 days followed by four cycles of multiagent chemotherapy (Memorial Sloan-Kettering Cancer Center [MSKCC] regimen). Pharmacokinetically guided topotecan dosing (target systemic exposure with area under the curve of 50 to 70 ng/mL/hr) was performed. Peripheral-blood stem cell (PBSC) harvest and surgical resection of residual primary tumor occurred after cycles 2 and 5, respectively. Patients achieving at least a partial response received myeloablative chemotherapy with PBSC rescue and radiation to the presurgical primary tumor volume. Oral 13-cis-retinoic acid maintenance therapy was administered twice daily for 14 days in six 28-day cycles.
Results: Thirty-one patients were enrolled onto the study. No deaths related to toxicity or dose-limiting toxicities occurred during induction. Mucositis rarely occurred after topotecan cycles (9.7%) in contrast to 30% after MSKCC cycles. Thirty patients underwent PBSC collection with median 31.1 × 10(6) CD34+ cells/kg (range, 1.8 to 541.8 × 10(6) CD34+ cells/kg), all negative for tumor contamination by immunocytochemical analysis. Targeted topotecan systemic exposure was achieved in 26 (84%) of 31 patients. At the end of induction, 26 patients (84%) had tumor response and one patient had progressive disease. In the overall cohort, 3-year event-free and overall survival were 37.8% ± 9.4% and 57.1% ± 9.4%, respectively.
Conclusion: This pilot induction regimen was well tolerated with expected and reversible toxicities. These data support investigation of efficacy in a phase III clinical trial for newly diagnosed HRNB.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures


Comment in
-
Determining the best dose for the individual patient.J Clin Oncol. 2011 Nov 20;29(33):4345-6. doi: 10.1200/JCO.2011.38.2572. Epub 2011 Oct 17. J Clin Oncol. 2011. PMID: 22010022 No abstract available.
Similar articles
-
Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.BMC Cancer. 2019 Oct 16;19(1):961. doi: 10.1186/s12885-019-6186-z. BMC Cancer. 2019. PMID: 31619207 Free PMC article.
-
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.J Clin Oncol. 2005 Jun 20;23(18):4039-47. doi: 10.1200/JCO.2005.02.097. J Clin Oncol. 2005. PMID: 15961757 Clinical Trial.
-
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).Clin Transl Oncol. 2015 Jul;17(7):521-9. doi: 10.1007/s12094-014-1273-8. Epub 2015 Jan 17. Clin Transl Oncol. 2015. PMID: 25596034
-
Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.Eur J Cancer. 2011 Mar;47(4):572-8. doi: 10.1016/j.ejca.2010.10.023. Epub 2010 Nov 26. Eur J Cancer. 2011. PMID: 21112775
-
Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review.Medicine (Baltimore). 2024 Nov 29;103(48):e40662. doi: 10.1097/MD.0000000000040662. Medicine (Baltimore). 2024. PMID: 39612452 Free PMC article. Review.
Cited by
-
Molecular imaging of adrenal neoplasms.J Surg Oncol. 2012 Oct 1;106(5):532-42. doi: 10.1002/jso.23162. Epub 2012 May 24. J Surg Oncol. 2012. PMID: 22628250 Free PMC article. Review.
-
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.JAMA. 2019 Aug 27;322(8):746-755. doi: 10.1001/jama.2019.11642. JAMA. 2019. PMID: 31454045 Free PMC article. Clinical Trial.
-
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1. Cancer. 2014. PMID: 24691684 Free PMC article.
-
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.J Clin Oncol. 2021 Oct 10;39(29):3229-3241. doi: 10.1200/JCO.21.00278. Epub 2021 Jul 28. J Clin Oncol. 2021. PMID: 34319759 Free PMC article.
-
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13. Cancer. 2022. PMID: 36101004 Free PMC article.
References
-
- Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55:97–120. - PubMed
-
- Canete A, Gerrard M, Rubie H, et al. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. J Clin Oncol. 2009;27:1014–1019. - PubMed
-
- Ladenstein R, Philip T, Lasset C, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998;16:953–965. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical